Edesa Biotech, Inc. (EDSA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.51 on 9 Oct 2026

9 buys0 sales at will0 planned sales

Fiscal year 2021, ended 30 Sep 2021, as filed

Revenue

$0.00

Net income

$13.34M

Free cash flow

$13.67M

Return on equity

-102.2%

Return on capital

-143.3%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
10 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$6.60K	0.2%
5 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$39.00K	2.5%
4 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$42.56K	2.6%
3 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$36.30K	2.7%
2 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$4.00K	0.3%
2 Mar 2026	Nijhawan Pardeep Chief Executive Officer	Bought	$2.28K	0.3%

49out of 100

Profitability 33

Financial strength 50

Growth n/a

Insiders 73

Strongest on insiders (73), weakest on profitability (33). A score of the business, not of the price.

Last 12 months

Only here

Bought

$233.05K

9 buys, 2 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan